<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02354274</url>
  </required_header>
  <id_info>
    <org_study_id>NARLAL 2</org_study_id>
    <nct_id>NCT02354274</nct_id>
  </id_info>
  <brief_title>Novel Approach to Radiotherapy in Locally Advanced Lung Cancer - Heterogeneous FDG-guided Dose Escalation With Concomitant Navelbine®</brief_title>
  <official_title>Novel Approach to Radiotherapy in Locally Advanced Lung Cancer - Heterogeneous FDG-guided Dose Escalation With Concomitant Navelbine®</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Olfred Hansen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Odense University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vejle Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Naestved Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aalborg Universitetshospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Herlev Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the effect of escalation of radiation dose to tumor and lymph nodes based on
      an inhomogeneous dose distribution controlled by FDG-PET positive areas compared to a
      standard homogeneous dose spread
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Locoregional control (Tumor recurrency is assessed by scheduled CT (of the thorax and upper abdomen)</measure>
    <time_frame>5-7 years</time_frame>
    <description>Tumor recurrency is assessed by scheduled CT (of the thorax and upper abdomen ) every 3 months combined with PET/CT every 9 months or if occurrence is clinically suspected. Suspicion of tumor relapse local, regional or distant should be verified by biopsy. Date of detected recurrence is the date off the imaging modality suspecting relapse. The patient will be censured at death without local relapse.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity (graded after CTC 4.0 assessed by physician)</measure>
    <time_frame>10 years</time_frame>
    <description>Acute and late toxicity graded after CTC 4.0 assessed by physician at scheduled follow-up visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>15 years</time_frame>
    <description>Time from randomization to exact date of death of any course</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival</measure>
    <time_frame>15 years</time_frame>
    <description>Time from randomization to date of progression, death, or occurency of metastatic disease</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">330</enrollment>
  <condition>NSCLC</condition>
  <arm_group>
    <arm_group_label>Standard: Homogene dose plan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment will be given over 33 treatments. The dose is 66 Gy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Escalation: Inhomogene dose plan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Radiation dose is increased to tumor and lymph nodes based on an inhomogeneous dose distribution determined by the most active ( FDG-PET criteria ) area of the node compared to a standard uniform dose distribution.
Treatment will be given over 33 treatments. The dose is as high as possible taking the tolerance of the normal tissue into consideration</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Escalated: Inhomogene dose plan</intervention_name>
    <arm_group_label>Escalation: Inhomogene dose plan</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Standard: Homogene dose plan</intervention_name>
    <arm_group_label>Standard: Homogene dose plan</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with histologically or cytologically proven locally advanced NSCLC stage IIB
             to IIIB

          -  Performance status 0-1

          -  Able to comply with treatment and follow study and follow-up procedures

          -  Women must have negative pregnancy test

          -  Signed, informed consent

          -  Plan for radiotherapy with conventional 66 Gy/ 33 F, which meets all dosing limits two
             normal tissue must be available

        Exclusion Criteria:

          -  Any unstable systemic disorder (including infection , unstable angina, congestive
             heart failure , severe liver , kidney or metabolic disease)

          -  Need for nasal oxygen

          -  Former thoracic radiotherapy, unless there is no significant overlap with previous
             fields

          -  Any other active malignant disease

          -  Unable to take oral medications or needing intravenous nutrition

          -  Ulcer

          -  Nursing women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Olfred Hansen, MD</last_name>
    <phone>+4565411867</phone>
    <email>olfred.hansen@rsyd.dk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <zip>9100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Svetlana Kunwald, MD</last_name>
    </contact>
    <investigator>
      <last_name>Svetlana Kunwald, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marianne M. Knap, MD</last_name>
    </contact>
    <investigator>
      <last_name>Marianne M. Knap, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <zip>2100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gitte F. Persson, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herlev University Hospital</name>
      <address>
        <city>Herlev</city>
        <zip>2730</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jon L. Andersen, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jon L. Andersen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Oncology, Naestved Hospital</name>
      <address>
        <city>Naestved</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kim Wederwang, MD</last_name>
      <email>kwd@regionsjaelland.dk</email>
    </contact>
    <investigator>
      <last_name>Kim Wedervang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Oncology, Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <zip>5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olfred Hansen, MD</last_name>
      <phone>+45 6541 1867</phone>
      <email>olfred.hansen@rsyd.dk</email>
    </contact>
    <investigator>
      <last_name>Olfred Hansen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tine Schytte, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Oncology, Vejle Hospital</name>
      <address>
        <city>Vejle</city>
        <zip>7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christa Haugaard, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christa Haugaard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2015</study_first_submitted>
  <study_first_submitted_qc>February 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2015</study_first_posted>
  <last_update_submitted>May 19, 2016</last_update_submitted>
  <last_update_submitted_qc>May 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>Olfred Hansen</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vinorelbine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

